Navigation Links
difficulties in Medical Technology

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

... and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global ...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...

July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair

... increased risk of early death, compared with their optimistic counterparts. Optimists reported having fewer health problems and fewer difficulties with work or daily routines, and they were generally happier, calmer and more peaceful. They experienced less pain, had more energy and reported ...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

... disorders, with typical symptoms usually emerging in early adulthood, including loss of muscle mass, pain and sensitivity, foot deformations and difficulties in walking. Human genome sequencing revealed that some CMT patients have mutations in a gene encoding tyrosyl-tRNA synthetase. While tRNA ...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

... clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time ...

Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy

... efficacy end point - the six-minute walk." Dr. Carl Pepine, MD, Professor of Medicine, University of Florida College of Medicine, discussed the difficulties of stem cell therapy in scar tissue. "Cells of the myoblast variety seem to be able to overcome this ... this is what's so exciting about ...

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

... by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial ...

Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009

... including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

... limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, ...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

... and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global ...

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

... among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including RAPAFLO(TM); difficulties or delays in manufacturing; patents and other intellectual property rights held by the Company and the ability to successfully enforce such rights ...

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

... data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; difficulties or delays in obtaining regulatory approval for ANX-514, including validating commercial manufacturers and suppliers and the potential for automatic ...

Transcept Pharmaceuticals to Report First Quarter 2009 Results

... alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates. ...

Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule

... including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the ...

Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs

... adaptive trial designs that were cited by respondents included understanding and implementing complex statistical methodologies as well as difficulties in medication supplies estimation and supply chain management. "Formal FDA guidance on adaptive trials implementation is expected later this ...

Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications

... that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may ...

Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting

... from those set forth in this release due to the risks and uncertainties inherent in Cylene's business including, without limitation, risks related to difficulties or delays in testing, obtaining regulatory approval for, producing and marketing its products; unexpected adverse side effects or inadequate ...

Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease

... significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, ...

CEL-SCI Corporation Releases Letter to Shareholders

... clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time ...

Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer

... that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including RAPAFLO(TM); difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; ...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

... including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the ...
Other Contents
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
(Date:8/29/2014)... researcher from the University of Texas Medical Branch at Galveston ... monoclonal antibodies can completely protect monkeys against a lethal dose ... a time when the disease is severe. , Thomas Geisbert, ... Nature discussing advances in Ebola treatment research. The ... the most deadly of pathogens, with fatality rates of up ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give One company, ... toothbrush. For every toothbrush purchased, Smile Squared gives one ... created by my wife and me after volunteering at ... of Smile Squared. “There, we saw children who had ... the same children didn't own a toothbrush. We wanted ...
(Date:9/2/2014)... Tuesday 2 September 2014: Health structures explain nearly ... according to the results of a joint ESC-OECD ... Aldo Maggioni. Clinical variables explained more than 80% ... a unique evaluation which combines clinical data and ... a fuller picture of the reasons some patients ...
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and ... the opening of its new office to be located ... Business Parkway, Suite D, Greer, SC 29651. This new ... a more convenient location in the Greenville area. , ... the physicians, hospitals and patients we serve, to ensure ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 ... for about a decade, primarily to help people ... time, there are three developed systems,” says Dana ... approaches substantively differ, the goals are much the ... support of some type of harmonica.” , The ...
(Date:9/2/2014)... During the fall season, before the ... winter months to prevent costly damage later on. Pasquali ... company, suggests these fall preventative home maintenance tips. , ... throughout fall to prevent build up of leaves and ... problems, pest infestations, wet basements, foundation damage and many ...
Breaking Medicine News(10 mins):Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Suggests These Maintenance Tips for Homeowners This Fall 2
Other TagsOther Tags